Menu
Recruiting NCT06387290

Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits

Phase III Interventional Chronic Pain Prescription Opioid Misuse Substance-Related Disorders Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mindfulness Oriented Recovery Enhancement, Patient-Centered Chronic Pain Management Visits.
Who it may be relevant to
Registry conditions: Chronic Pain, Prescription Opioid Misuse, Substance-Related Disorders, Pain. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The primary aim of this implementation-effectiveness trial is to examine the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) and patient-centered chronic pain management visits in primary care as interventions to reduce chronic pain, improve quality of life, and reduce opioid-related harms among chronic pain patients on long-term opioid therapy.

Interventions

  • Behavioral Mindfulness Oriented Recovery Enhancement
    Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.
  • Behavioral Patient-Centered Chronic Pain Management Visits
    Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).

Primary outcome measures

  • Opioid Misuse [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
  • Chronic Pain [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
Secondary outcome measures (6)
  • Change in Quality of Life [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
  • Opioid Dosing [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
  • Opioid Craving [Time frame: Daily from baseline through month 4]
  • PTSD Symptoms [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
  • Depression [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]
  • Generalized Anxiety [Time frame: Change from baseline through study completion (assessed at 3-, 6-, 9-, and 12-months follow-up)]

Eligibility criteria

Inclusion criteria

  • Age 18 +
  • Current chronic pain diagnosis (pain for ≥3 months) determined by physician assessment
  • Prescribed long-term opioid therapy (≥3 months)
  • Score >=3 on the Pain Enjoyment General Activity scale
  • Score >=9 on the Current Opioid Misuse Measure OR lifetime psychiatric or substance use disorder diagnosis OR benzodiazepine use OR history of overdose OR patient or physician determination that risks of opioid use may outweigh the benefits of opioid use

Exclusion criteria

  • Chronic pain due to a cancer diagnosis
  • Active suicidal intent, schizophrenia, psychotic disorder
  • Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, Mindfulness-Based Relapse Prevention, or Mindfulness-Oriented Recovery Enhancement

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 3 centers
  • UCSD Health — La Jolla
  • Rutgers University Primary Care Clinics — New Brunswick
  • University of Utah Primary Care Clinics — Salt Lake City

Identifiers

NCT: NCT06387290 · 00172836

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗